middle.news
BCAL Diagnostics Sees Strong Early Demand for Avantect Cancer Tests
8:36am on Thursday 5th of February, 2026 AEDT
•
Healthcare
Read Story
BCAL Diagnostics Sees Strong Early Demand for Avantect Cancer Tests
8:36am on Thursday 5th of February, 2026 AEDT
Key Points
Over 1,000 enquiries and 20 tests completed within 11 days of Avantect launch
Testing rollout expanding through Sonic Healthcare pathology sites in NSW, QLD, and VIC
Unit test pricing generating positive gross margins at current volumes
BREASTESTplus shows 90% sensitivity in women with dense breasts, regulatory approval expected by mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE